MarketCap
Facebook
X
Telegram
AVEO Pharmaceuticals DIO Ratio | AVEO
Annual DIO Ratio AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 149 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 149 | 149 | 149 |
Quarterly DIO Ratio AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 27.9 | 44.9 | 62.8 | 65.3 | 32.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 65.3 | 27.9 | 46.7 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
AbbVie
ABBV
|
91.6 | $ 293.87 | 0.19 % | $ 520 B |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.5 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Axon Enterprise
AXON
|
98.8 | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
373 | - | - | $ 83.9 M |  Canada |
 |
Bristol-Myers Squibb Company
BMY
|
68.7 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
570 | - | -3.76 % | $ 3.47 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
221 | $ 4.0 | -6.76 % | $ 48.8 M |  Israel |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
235 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
352 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
343 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CorMedix
CRMD
|
308 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.1 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
430 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
Merck & Co.
MRK
|
142 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
56.8 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
455 | - | - | $ 2.02 B | USA |
 |
Novartis AG
NVS
|
130 | $ 163.39 | -0.18 % | $ 317 B |  Schweiz |
 |
Omeros Corporation
OMER
|
484 | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Puma Biotechnology
PBYI
|
44.7 | $ 8.13 | -3.22 % | $ 407 M | USA |